Aurobindo Pharma unit partners with MSD to foray into contract manufacturing operations

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-06-03 07:12 GMT   |   Update On 2024-06-20 19:08 GMT
Advertisement

Hyderabad: Drug firm, Aurobindo Pharma has said that TheraNym Biologics, a wholly-owned subsidiary of the Company and an affiliate of CuraTeQ, has entered into agreement with MSD to establish a plant as it looks to enter the contract manufacturing operations for biologicals. TheraNym Biologics and MSD, signed a Master Service Agreement (MSA).

As part of the arrangement, 
Theranym will invest around Rs.1,000 crores for 
establishing manufacturing facility with large scale bioreactors for any mammalian cell culture product and a vial filling isolator line for commercial drug product manufacturing upto 25-30 mn vials per annum, drug major stated in a BSE filing.
"TheraNym will build the manufacturing facility, manufacture the products and supply to MSD as per the arrangement," it noted.

In October last year, CuraTeQ Biologics and Merck Sharp & Dohme Singapore Trading Pte Ltd and its affiliates (MSD) signed a letter of intent for contract manufacturing operations involving biologicals. Originally, the parties aimed to finalize negotiations by March 31, 2024. However, they later agreed to extend the deadline until May 31.

Read also: Aurobindo Pharma commissions 4 manufacturing plants for PenicillinG, other products   

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The Company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Read also: Aurobindo Pharma appoints T Vijaya Kumar as President - RnD (Specialty Drug Delivery)   

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News